thrombopoiesis

(redirected from thrombopoietic)
Also found in: Dictionary.

thrombopoiesis

 [throm″bo-poi-e´sis]
2. thrombocytopoiesis. adj., adj thrombopoiet´ic.

throm·bo·poi·e·sis

(throm'bō-poy-ē'sis),
Precisely, the process of a clot forming in blood, but generally used with reference to the formation of blood platelets (thrombocytes).
[thrombo- + G. poiēsis, a making]

thrombopoiesis

/throm·bo·poi·e·sis/ (-poi-e´sis)
2. thrombocytopoiesis.thrombopoiet´ic

thrombopoiesis

(thrŏm′bō-poi-ē′sĭs)
n.
1. The process of blood clot formation.
2. The formation of blood platelets.

throm′bo·poi·et′ic (-ĕt′ĭk) adj.

throm·bo·poi·e·sis

(throm'bō-poy-ē'sis)
Precisely, the process of a clot forming in blood, but generally used with reference to the formation of blood platelets (thrombocytes).
[thrombo- + G. poiēsis, a making]

thrombopoiesis

1. thrombogenesis.
2. thrombocytopoiesis.
References in periodicals archive ?
Reticulated platelets in the evaluation of thrombopoietic disorders.
Currently, romiplostim is the only thrombopoietic treatment for adult chronic ITP for which there is three years of follow-up data," said Professor Adrian Newland, Department of Haematology, The Royal London Hospital, Whitechapel, London, UK.
aTyr's lead program, scheduled for a pre-IND meeting at the FDA in September, is a novel protein therapeutic, ATYR0030, with thrombopoietic activity that is initially being developed to treat thrombocytopenia in patients with myelodyspastic syndromes (MDS).
Currently, Nplate is the only thrombopoietic ITP treatment for which there are over two years of follow-up data," said James Bussel, M.
The invention enables simulating the thrombopoietic process in virtual patients where different therapies are applied.
These are the first clinical results on AKR-501 that show it may be a safe thrombopoietic agent that may lessen or eliminate the need for platelet transfusions, benefiting patient health, and, possibly, lowering health care costs.
An Open-Label, Unit Dose-Finding Study Evaluating the Safety and Platelet Response of Novel Thrombopoietic Protein (AMG531) in Thrombocytopenic Adult Patients with Immune Thrombocytopenic Purpura (ITP) [Abstract 2058]
In addition to MYLOTARG(R) (gemtuzumab ozogamicin for Injection), the company manufactures Neumega(R) (oprelvekin), a thrombopoietic growth factor for preventing severely lowered platelet counts and the corresponding need for platelet transfusions following chemotherapy.
Based on an evaluation of the first 12 patients enrolled in the study, Gordon and his associates concluded that Neumega rhIL-11 has thrombopoietic activity, or the ability to increase platelet production, at all doses studied.